Think about how long it took the smartphone industry to make a dent in landline culture — years of incremental hardware gains, a few pivotal software moments, and then suddenly it just clicked. Cancer research doesn’t move that fast, and it never pretends to. But what’s happening at Memorial Sloan Kettering Cancer Center right now with colorectal cancer treatments feels like one of those inflection points where the incremental gains start stacking up into something you can actually see. MSK’s latest reporting on new colorectal cancer treatments makes the case plainly: death rates are dropping, early detection is improving, and the goal is no longer just survival — it’s keeping people’s lives intact while they fight.
That matters right now because colorectal cancer is the third most common cancer in both men and women in the United States. It is not a rare disease you read about and forget. It is a disease that touches most extended families at some point. And while the trend lines are moving in the right direction, a disturbing counter-current is pulling younger people into the statistics in ways researchers are still scrambling to explain.
- Colorectal cancer is the third most common cancer diagnosis for both men and women in the U.S.
- The American Cancer Society reported in 2026 that colorectal cancer death rates dropped by 1.5% per year over the past decade for both men and women.
- MSK created the first center in the world dedicated specifically to colorectal and gastrointestinal cancers in adults under 50: the Center for Young Onset Colorectal and Gastrointestinal Cancer.
- The FDA approved an immunotherapy treatment in 2026 to treat certain rectal cancers — a development significant enough that MSK updated its original January 2026 report in October to include it.
- Canadian researchers, separately, have identified cancer signals in blood up to eight years before a formal diagnosis — suggesting early detection could eventually become a routine blood test rather than a reactive colonoscopy.
Why Younger People Are Getting Colorectal Cancer — And Why Nobody Has a Clean Answer Yet
The part of this story that should genuinely unsettle people is not the disease itself — it’s the fact that we don’t know why incidence rates are rising in adults under 50. According to MSK, researchers there are actively racing to understand this trend. Not studying it from a comfortable academic distance. Racing. That word choice in their own reporting is telling. They built an entire dedicated center for young-onset colorectal and GI cancer specifically because the existing infrastructure wasn’t designed with this demographic in mind. Young adults face different lifestyle considerations, fertility concerns, and long-term treatment consequences than patients in their 60s and 70s. The medical system has historically handled them as an afterthought.
Here’s the contrarian read that the field doesn’t love to admit: for all the progress in treatment options, the oncology world has been slow to interrogate its own screening assumptions. Colonoscopy guidelines have crept younger — the U.S. now recommends starting at 45 — but the pace of that institutional adjustment has lagged behind the actual data on rising young-onset cases. If Canadian researchers can detect cancer signals in blood up to eight years before a diagnosis, per reporting from Hospital News, then the real question isn’t just how we treat colorectal cancer better. It’s why we’re still primarily catching it late. A blood test that flags cancer eight years out isn’t science fiction anymore. The gap between what the research can do and what your average primary care visit actually offers remains enormous.
The FDA Approval and What “Preserving Quality of Life” Actually Means in Practice
The October 2026 FDA approval of an immunotherapy to treat certain rectal cancers is the kind of development that gets buried in institutional press releases and deserves more oxygen. Immunotherapy as a concept has been circulating in oncology for years, but approvals for specific cancer subtypes are where it becomes real and available to actual patients. MSK’s updated reporting makes clear this is not a hypothetical — it is a treatment option that exists now.
The phrase “preserve quality of life” gets used so often in medical communications that it can start to feel hollow. But in the context of colorectal cancer specifically, it carries real weight. Surgery for rectal cancer can result in permanent colostomy bags. It can affect bowel function, sexual function, and continence for years or permanently. When MSK says quality of life is part of the treatment equation, they mean that newer approaches — including immunotherapy and more precisely targeted surgical and radiation protocols — are being designed to keep those outcomes from becoming the default. That is a meaningful shift in how the specialty defines success.
The parallel story at Huntsman Cancer Institute, where a Utah grandfather named Russ Smith gained access to a new drug called daraxonrasib for pancreatic cancer after chemotherapy stopped working, illustrates what this era of cancer treatment actually looks like on the ground. Not a single miracle drug, but a broadening menu of options — clinical trials, targeted therapies, institution-specific access — that can extend life and buy time in ways that weren’t available even five years ago. The connective tissue across these stories, whether it’s colorectal cancer at MSK or pancreatic cancer at Huntsman, is that major cancer centers are functioning less like hospitals and more like research platforms with patient care attached. That model produces results. It also raises real access questions that nobody in mainstream tech-adjacent media talks about enough — which is a conversation worth having even if this industry, like the tech sector grappling with its own structural inequities, tends to celebrate the innovation while soft-pedaling who actually gets to use it.
The same discipline that separates organizations doing serious long-term work from those chasing short-term wins — the kind of methodical, adaptive approach you see in fields that actually build things meant to last — is exactly what distinguishes MSK’s work here. They are not announcing cures. They are reporting progress, updating findings, and building infrastructure for patients who didn’t have advocates in the system before.
So here’s the verdict: colorectal cancer treatment in 2026 is genuinely improving, the data backs that up, and the FDA approval of rectal cancer immunotherapy this year is a concrete milestone worth paying attention to. But the rising tide of young-onset cases and the persistent gap between research capability and accessible screening are the unresolved tension this field has to answer — and it hasn’t yet. The wins are real. The work isn’t close to done.
Watch the Breakdown
Sources
- New Colorectal Cancer Treatments at MSK Aim To Reduce Deaths and Preserve Quality of Life — www.mskcc.org
- Breakthrough Drug Brings Hope to Utah Grandfather with Pancreatic Cancer — healthcare.utah.edu
- Canadian study finds cancer signals in blood up to eight years before diagnosis — www.hospitalnews.com
